Enveric Biosciences, Inc.

Name: Enveric Biosciences, Inc. standardized financial statements, quarterly
Creator: Listed

ENVBNasdaqCIK 890821HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$3.0m, Q2 FY2026

Net income−$3.0m, Q2 FY2026

Enveric Biosciences, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Cost of revenue	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Gross profit	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Research and development	$k	1,281	1,721	506	565	803	967	746	1,260	402	372	346	1,355
Selling, general and administrative	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Operating income	$k	(3,448)	(2,384)	(2,477)	(1,898)	(2,083)	(3,174)	(2,188)	(2,519)	(1,874)	(2,194)	(1,633)	(3,027)
Interest expense	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$k	6.6	22.3	1.7	0.0	0.0	7.2	not reported	not reported	not reported	not reported	not reported	not reported
Net income	$k	(2,822)	(3,436)	(2,457)	(1,879)	(2,084)	(3,155)	(2,185)	(2,519)	(1,874)	(2,194)	(1,633)	(3,028)
Diluted EPS	$ per share	(1.30)	not reported	(9.21)	(3.72)	(43.10)	not reported	(14.58)	(11.65)	(10.81)	not reported	(1.08)	(0.76)
Basic EPS	$ per share	(1.30)	not reported	(9.21)	(3.72)	(43.10)	not reported	(14.58)	(11.65)	(10.81)	not reported	(1.08)	(0.76)

Balance sheet

Cash and equivalents$8.3m, Q2 FY2026

Shareholders' equity$8.1m, Q2 FY2026

Enveric Biosciences, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$k	4,267	2,288	6,356	3,503	3,112	2,241	4,294	2,850	3,758	4,677	4,909	8,296
Current assets	$k	5,827	3,582	8,229	5,520	4,338	2,735	4,835	3,307	4,166	4,937	5,375	8,793
Total assets	$k	6,619	4,300	8,850	6,052	4,790	3,083	5,102	3,548	4,362	5,096	5,521	8,944
Current liabilities	$k	4,184	2,344	2,368	645	839	1,490	1,184	1,364	906	918	461	861
Total liabilities	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Long-term debt	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Current portion of debt	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Short-term borrowings	$k	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$k	2,436	1,956	6,482	5,406	3,951	1,593	3,918	2,185	3,456	4,178	5,061	8,083

Cash flow

Operating cash flow−$2.4m, Q2 FY2026

Capital expenditure−$15, Q4 FY2023

Enveric Biosciences, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$k	(2,740)	(1,751)	(2,598)	(2,889)	(927)	(1,312)	(2,392)	(1,890)	(2,075)	(1,785)	(2,257)	(2,445)
Capital expenditure	$k	0.0	(0.0)	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported

Diluted shares (weighted)3.99m, Q2 FY2026

Enveric Biosciences, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q2 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	k shares	1,787	2,078	2,108	2,165	267	506	48.4	150	216	313	1,510	3,987

Shares outstanding: 4.48m at Aug 12, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. Listed shows no prices and gives no investment advice.